Zosuquidar 3HCl

카탈로그 번호S1481 배치:S148102

인쇄

기술 자료

화학식

C32H31F2N3O2.3HCl

분자량 636.99 CAS 번호 167465-36-3
용해도 (25°C)* 시험관 내(In vitro) DMSO 127 mg/mL (199.37 mM)
Water 23 mg/mL (36.1 mM)
Ethanol Insoluble
생체 내(In Vivo) (개별적으로 순서대로 용매를 제품에 첨가하십시오.)
Homogeneous suspension
CMC-NA
≥5mg/ml Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
* <1 mg/ml은 약간 용해되거나 불용해됨을 의미합니다.
* Selleck은 모든 화합물의 용해도를 자체적으로 테스트하며, 실제 용해도는 게시된 값과 약간 다를 수 있습니다. 이는 정상적인 현상이며, 약간의 배치 간 변동으로 인해 발생합니다.
* 실온 배송 (안정성 테스트 결과 이 제품은 냉각 조치 없이 배송될 수 있음을 보여줍니다.)

원액 준비

생물학적 활성

설명 Zosuquidar 3HCl은 세포 무첨가 분석에서 60 nM의 Ki를 가진 P-glycoprotein 매개 다제 내성의 강력한 조절제입니다. 임상 3상.
표적
P-gp
(Cell-free assay)
60 nM(Ki)
시험관 내(In vitro)

LY335979 competitively inhibits equilibrium binding of Pgp by blocking [3H]azidopine photoaffinity labeling of the Pgp in CEM/VLB100 plasma membranes. LY335979 alone shows the cytotoxicity to drug-sensitive and MDR cell lines with IC50 ranging from 6 μM-16 μM and produces its ability to completely reverse the resistance of the oncolytics to the MDR cell lines P388/ADR, MCF7/ADR, 2780AD, or UCLA-P3.003VLB at concentration of 0.1 and 0.5 μM. LY335979 significantly restores drug sensitivity in P-gp-expressing leukemia cell lines including K562/HHT40, K562/HHT90, K562/DOX and HL60/DNR, and enhances the cytotoxicity of anthracyclines and ozogamicin (Mylotarg) in primary AML blasts with active P-gp. A latest paper indicates that LY335979 completely inhibits apically directed transport of (Z)-endoxifen in the ABCB1-transduced cells.

프로토콜 (참조)

키나아제 분석:

[1]

  • ATPase 분석

    P-gp ATPase 활성은 ATP로부터 무기 인산염이 유리되는 것으로 측정된다. 이 분석은 96-웰 플레이트에서 37°C로 90분간 수행된다. 막(8 μg-10 μg 단백질)은 5 mM 아지드화 나트륨, 1 mM 우아바인, 1 mM EGTA, 3 mM ATP, 5 mM 포스포엔올피루브산과 3.6 units/mL 피루브산 키나아제로 구성된 ATP 재생 시스템을 포함하는 버퍼 A 100 μL 총 부피 내에서 1 mM 바나듐산 나트륨 존재 및 부재 하에 배양된다. P-gp ATPase 활성은 전체 ATPase 활성 중 바나듐산염에 민감한 부분으로 정의된다. 플레이트는 검출 용액 첨가 3분 후 판독된다. 흡광도는 마이크로타이터 디쉬 리더를 사용하여 690 nm에서 측정된다. 인산염 표준 곡선을 사용하여 형성된 인산염의 μmol을 계산한다. 샘플은 3회 반복 측정된다.

세포 분석:

[1]

  • 세포주

    CEM/VLB100, P388/ADR, MCF7/ADR, 2780AD, and UCLA-P3.OO3VLB cells

  • 농도

    0.05 μM to 5 μM

  • 배양 시간

    72 hours

  • 방법

    Cell viability is determined using a modified the MTT dye reduction method. Cells are harvested during logarithmic growth phase, and seeded in 96-well plates. The cells are then cultured for 72 hours in the presence of oncolytics with or without modulators. MCF-7 and MCF-7/ADR cells are incubated 24 hours before the addition of the drug with and without the LY335979. LY335979 is prepared as 2 mM DMSO stocks and added to wells to give final concentrations ranging from 0.05 to 5 μM. After 72 hours, 20 μL of freshly prepared MTT(5 mg/mL in Dulbecco's PBS) is added to each well and incubated for 4 hours in a 37 °C incubator containing 5% CO2. Cells are pelleted in a Sorvall RT6000B centrifuge, 70 μL of medium is carefully removed from each well, and 100 μL of 2-propanol/0.04 N HC1 is added. Cells are resuspended 5-10 times with a Multipipettor or until no particulate matter is visible. Plates are immediately read on a Titertek Multiskan MCC/340 microplate reader Flow Laboratories with a test wavelength of 570 nm and a reference wavelength of 630 nm. Controls are measured in quadruplicate and modulators are measured in duplicate. Cytotoxicity analyses are also performed using the CeliTiter 96 AQueous assay kit.

동물 연구:

[1]

  • 동물 모델

    P388 or P388/ADR cells are implanted by i.p. injection into female BDF1 mice.

  • 용량

    ≤30 mg/kg

  • 투여

    Administered via i.p. and i.v.

참조

  • https://pubmed.ncbi.nlm.nih.gov/8797588/
  • https://pubmed.ncbi.nlm.nih.gov/18271955/
  • https://pubmed.ncbi.nlm.nih.gov/21378205/

고객 제품 검증

Inhibition of doxorubicin compartmentalization by combined treatment with inhibitors of Abcb1 and Abcc1. A: The cells had been incubated with vehicle or 1 uM  zosuquidar  plus 15 uM  MK571 (ZO/MK), before addition of 1 uM doxorubicin (Doxo) and further cultivation in serum-free medium for 16 h. Shown are typical images of doxorubicin (red) and Hoechst 33342 (blue) fluorescence in Sgpl1<sup>+/+</sup> - and Sgpl1<sup>-/-</sup> -MEFs after treatment as indicated. Two images of Sgpl1<sup>-/-</sup> -cells treated with doxorubicin plus ZO/MK were selected to show the range of the cellular response. B: Hoechst 33342 staining in MEFs that had been incubated with ZO/MK in the absence of doxorubicin.

데이터 출처 [ J Lipid Res , 2014 , 10.1194/jlr.M052761 ]

Effects of zosuquidar treatment on Zn uptake and accumulation in T. japonicus whole bodies for 24 h. Upper part in each picture represents Newport Green™ PDX Acetoxymethyl Ether, and lower parts merged images. (a-c) T. japonicus not treated with Zn. (d-f) T. japonicus treated with Zn. (g-i) T. japonicus treated with Zn and zosuquidar.

데이터 출처 [ Aquat Toxicol , 2014 , 156C, 135-147 ]

<p>Effect of P-gp expression on cell survival and proliferation of DNR and Zosuquidar(ZSQ) treated cells.</p>

데이터 출처 [ Pharmacol Res , 2013 , 67(1), 79-83 ]

Inhibition of B-A steady state fluxes of digoxin and rhodamine 123 by increasing concentrations of zosuquidar (ZSQ). The iP-gp cell monolayers were investigated for digoxin (A) and rhodamine 123 (B) transport in the presence of increasing concentrations of zosuquidar (0.002–2.0 μM). The cells were preincubated with zosuquidar 10 min before addition of 3.12 μM rhodamine 123 or tracer amount of [3H]-digoxin at the abluminal site for B-A transport in a period of 120 min. The fluxes were estimated from the linear part of the accumulation curves. Values are presented as means ± SEM of three individual cell passages with two individual permeable supports (n =3, total N = 6).

데이터 출처 [ , , Eur J Pharm Sci, 2018, 112:112-121 ]

Selleck's Zosuquidar 3HCl 인용됨 35 출판물

Pharmacological strategies to enhance the response of hepatoblastoma to chemotherapy through MDR1 inhibition [ Acta Pharmacol Sin, 2026, 10.1038/s41401-026-01791-z] PubMed: 42026237
Development of PROTACs for targeted degradation of oncogenic TRK fusions [ bioRxiv, 2025, 2025.06.18.660465] PubMed: 40666929
Inhibition of the transmembrane transporter ABCB1 overcomes resistance to doxorubicin in patient-derived organoid models of HCC [ Hepatol Commun, 2024, 8(5)e0437] PubMed: 38696353
Functional Blood-Brain Barrier Model with Tight Connected Minitissue by Liquid Substrates Culture [ Adv Healthc Mater, 2022, e2201984] PubMed: 36394091
Overcoming Resistance to Anti–Nectin-4 Antibody-Drug Conjugate [ Mol Cancer Ther, 2022, 21 (7): 1227–1235.] PubMed: None
Overcoming Resistance to Anti-nectin-4 Antibody-Drug Conjugate [ Mol Cancer Ther, 2022, molcanther.0013.2022] PubMed: 35534238
Brain endothelial cells metabolize glutamate via glutamate dehydrogenase to replenish TCA-intermediates and produce ATP under hypoglycemic conditions [ J Neurochem, 2021, 157(6):1861-1875] PubMed: 33025588
Heat Shock Protein Inhibitor 17-Allyamino-17-Demethoxygeldanamycin, a Potent Inductor of Apoptosis in Human Glioma Tumor Cell Lines, Is a Weak Substrate for ABCB1 and ABCG2 Transporters [ Pharmaceuticals (Basel), 2021, 14(2)107] PubMed: 33573093
The blood-brain barrier studied in vitro across species [ PLoS One, 2021, 16(3):e0236770] PubMed: 33711041
Characterization of human pregnane X receptor activators identified from a screening of the Tox21 compound library [ Biochem Pharmacol, 2020, S0006-2952(20)30604-3] PubMed: 33333074

반품 정책
Selleck Chemical의 무조건 반품 정책은 고객에게 원활한 온라인 쇼핑 경험을 보장합니다. 구매에 어떤 식으로든 불만족하시면, 수령일로부터 7일 이내에 모든 품목을 반품하실 수 있습니다. 제품 품질 문제(프로토콜 관련 문제 또는 제품 관련 문제)가 발생하는 경우, 원래 구매일로부터 365일 이내에 모든 품목을 반품하실 수 있습니다. 제품 반품 시 아래 지침을 따르십시오.

배송 및 보관
Selleck 제품은 실온에서 운송됩니다. 실온에서 제품을 받으셨더라도 안심하십시오. Selleck 품질 검사 부서에서 한 달간의 상온 보관이 분말 제품의 생물학적 활성에 영향을 미치지 않음을 확인하는 실험을 수행했습니다. 수령 후, 데이터시트에 설명된 요구 사항에 따라 제품을 보관하십시오. 대부분의 Selleck 제품은 권장 조건에서 안정적입니다.

인간, 수의학 진단 또는 치료 용도로 사용하지 마십시오.